Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
暂无分享,去创建一个
M. Wilhelm | J. Hansson | V. Höiom | Rainer Tuominen | S. Egyházi Brage | I. Das | F. Costa Svedman | Rodolfo Franco Marquez